Abstract
The Case: Low-Threshold Access Points in British Columbia
Study Design
Data Collection

| Group and inclusion criteria | Interview themes (key informants) |
|---|---|
| Interview questions (participants) | |
| Key informants | |
| Inclusion criteria
•
Identifieda as someone with expertise in one or several of these domains: ◦
Law and/or
◦
Research/Scholarship and/or
◦
Advocacy and/or
◦
Policy-making and/or
◦
Enforcement
|
We tailored the questions to the domain(s) of expertise of each key informant. Core themes and sub-themes: Theme 1: Access points in BC, pre-legalization
•
History and specificities of BC and its LTAPs
•
Context in which these LTAPs operated pre-legalization
•
Role of LTAPs for people who use CTP
Theme 2: Access to cannabis as a medicine, pre-legalization •
History and specificities of use of/access to CTP in BC
•
Challenges faced by people who use CTP
•
Profile of people who use CTP in BC
Theme 3: Access points in BC, post-legalization •
Uniqueness of BC in comparison to other jurisdictions
•
Impact of legalization on LTAPs in BC
•
Consequences of closing LTAPs
•
Challenges faced by LTAPs that remain open
Theme 4: Access to cannabis as a medicine, post-legalization •
Impact of legalization on people who use CTP
•
Thoughts on remaining access to cannabis for people who use(d) LTAPs and have therapeutic needs
•
Consequences specific to people who use CTP Concluding questions
•
What works/does not work in BC’s approach to LTAPs?
•
What is missing or could be done differently?
•
What gaps exist for people who use CTP?
•
What documents should we add to the case study?
|
| People with operational experience | |
| Inclusion criteria
•
19 years or older
•
Residing in BC
•
Able/willing to complete interview
•
Direct experience of opening and/or running a LTAP (or LTAPs) • LTAP(s) meet(s) definitionb
• LTAP(s) located in BC
• Direct experience in role(s):
• Founder (or co-founder)
• Management or leadership
• Governance (board of directors)
Frontline staff or volunteer
Grower/baker/producer
|
After answering three pre-interview questionnaire (i.e., type of LTAP(s), roles, and years of experience), participants were asked the following questions. We tailored the questions to the stated LTAP(s) and role(s): Introduction and background Please tell me about your work as it relates to cannabis, including anything you think is important for me to know about and would be helpful to set the stage for our discussion. Access point, role, and raison d’être
•
Can you describe how, why, and when you got involved with [type of LTAP]?
•
Can you explain in a bit more details your role and what your involvement looks(ed) like?
•
In your own words, what is(was) the goal of this LTAP? Who does(did) it serve?
•
In your experience, why was this type of LTAP needed? Situating the experience on context, pre-legalization
•
When you became involved with this LTAP, where there other similar access points in BC? What was going on in the province?
•
Can you describe the general context in which your LTAP operated before cannabis legalization?
•
Can you describe the local and provincial context? ◦
What challenges did you face?
◦
What opportunities did you encounter?
◦
What was your experience with policing and the criminal justice system?
•
Going into legalization, how was the LTAP affected? Were any measures taken to keep the LTAP open, close it, protect it somehow?
•
Going into cannabis legalization, did you personally have any hopes and/or worries? Situating the experience on context, after legalization
•
Can you describe what happened to your LTAP after cannabis legalization?
•
If it remained open: How would you describe the local and provincial context post-legalization? ◦
What challenges did you face?
◦
What opportunities did you encounter?
◦
What was your experience with policing and the criminal justice system?
◦
What was your experience with the cannabis enforcement system?
•
If your site has closed: Can you walk me through the steps leading to the closure? ◦
Did legalization contribute to the closure? How?
◦
Can you describe who was left behind following the closure?
Access to cannabis as a medicine, pre- and post-legalization •
Based on your experience, what was the experience of people who use CTP before legalization? ◦
Access
◦
Products
◦
Challenges
◦
Opportunities
•
What is the experience of the same people now, post-legalization? Has anything changed?
•
Can you explain why LTAPs have (historically and in BC) been important to people who use CTP?
•
Can you describe the differences between the current government-sanctioned stores and LTAP from the perspective of therapeutic users? Concluding questions
•
What works/does not work in BC’s approach to LTAPs?
•
What is missing or could be done differently?
•
What gaps exist for people who use CTP?
•
What documents should we add to the case study?
|
| People with lived experience | |
| Inclusion criteria
•
19 years or older
•
Residing in BC
•
Able/willing to complete interview
•
Lived/living experience of chronic illness and/or chronic symptoms
•
Lived experience of accessing a LTAP (or LTAPs): |
After completing the pre-interview questionnaire (see Tables 2 and 3), participants were asked the following questions: Introduction and background Please tell me about your experience with cannabis, including anything you think is important for me to know about and would be helpful to set the stage for our discussion. Cannabis use and access at LTAP (as defined below)
•
Can you describe why and when you started using CTP?
•
Can you explain how cannabis is therapeutic for you?
•
How do you use it?
•
What works for you?
•
I understand that you have experience accessing cannabis at a [type of access point]. Can you tell me more about that experience?
•
Why are(were) places like [type of access point] important to you as a person who uses CTP?
•
What are the challenges faced by people who use CTP in accessing cannabis as a medicine? Access points before and after legalization
•
Can you describe your experience accessing a [type of access point] before cannabis legalization?
•
Has anything change since legalization? How so?
•
How has legalization affected you as someone who uses cannabis as a medicine? Concluding questions
•
What works/does not work in BC’s approach to LTAP?
•
What gaps exist for people who use CTP?
|
Data Analysis

Results
| n (%) | |
|---|---|
| Age (years) | |
| 31–40 | 3 (25) |
| 51–60 | 5 (42) |
| 61–70 | 2 (17) |
| >71 | 2 (17) |
| Gender | |
| Cisgender man | 5 (42) |
| Cisgender woman | 7 (58) |
| Ethnicity | |
| European descent (White) | 12 (100) |
| Housing | |
| Unhoused | 1 (8) |
| Renting (room or apartment) | 8 (67) |
| Owning (condo or house) | 3 (25) |
| Income | |
| $10,000-$19,999 | 6 (50) |
| $20,000-$29,999 | 4 (33) |
| $30,000-$39,999 | 1 (8) |
| Unknown | 1 (8) |
| Sources of incomea | |
| Income assistance | 8 (66) |
| Full-time employment | 1 (8) |
| Part-time employment | 2 (17) |
| Pension/employment insurance | 2 (17) |
| Highest level of education completed | |
| Less than high school | 4 (33) |
| High school | 1 (8) |
| Registered trade or apprenticeship certificate or diploma | 1 (8) |
| College | 2 (17) |
| University (undergraduate – bachelor’s degree) | 2 (17) |
| University (undergraduate – master’s degree) | 2 (17) |
| n (%) | |
|---|---|
| Frequency | |
| Multiple times a week | 1 (8) |
| Once a day | 2 (17) |
| Multiple times a day | 9 (75) |
| Reasonsa | |
| For therapeutic use for a chronic illness or chronic symptoms | 12 (100) |
| For your own physical and mental wellness | 12 (100) |
| For recreational use (fun) or social use | 4 (33) |
| For spiritual use or traditional medicine purposes | 1 (8) |
| Other: for additional benefit of being more creative | 1 (8) |
| Preferred mode of consumptiona | |
| Ingesting edible products | 10 (83) |
| Smoking joints without tobacco | 5 (42) |
| Smoking using a pipe | 2 (17) |
| Vaporizing and vaping | 2 (17) |
| Applying on the skin | 3 (25) |
| Using suppositories | 1 (8) |
Accessing Community, Medicine, and Space
Accessing Community
Participants explained that accessing a community centered around the creation and sharing of knowledge played an important role in the process of becoming a medical cannabis user. Community was made up of staff working in low-threshold access points, many of whom had lived experience of medicating with cannabis as well as professional experiences working in the field of cannabis in various roles (e.g., intake, sales, production, management), and peers who had acquired knowledge through their own experience and their interactions with others.
Yeah, ‘cause I missed a major point, and that is the community. The community. So many times, I’ve said to [name], there is not a better university I could have gone to on the planet. Ok, I’m not saying I know everything about everything; I don’t. I’ve learned so much though, because of the people that I have met since the nineties (…). And not only have I learned about, you know, cannabis as a medicine and the politics surrounding it and why it got turned illegal in the first place and so many things! But I’ve met so many beautiful humans and each one of us is a gold mine of knowledge. (Participant 10, lines 210–218)
By acting as a knowledge community, low-threshold access points allowed participants to learn in ways that were not available through the health care system nor the medical cannabis program or the licensed retail stores opened post-legalization, as we note below. When asked why accessing knowledge in community was important to them as medical cannabis users, participants explained that there is a clear connection between learning and medicating.
(…) The knowledge of these people, [name of access point]’s crew, was indispensable! They knew stuff that I never dreamed of. They introduced me to the Cannoil1 products and they had more compassion, knowledge and guidance than my pharmacy manager or doctor, literally. Quite literally, I put them above the medical institution and the pharmacies. Much, much higher in value.
Interviewer: In terms of the kind of information or the depth of information?
Both. Both. Yes. I didn’t know what CBD was. They guided me through that. And I didn’t know what Cannoil was so, the depth of information, the variety of information, the um, advice and dosage, all of it. I couldn’t believe that [name of access point]’s crew was privy to this knowledge. It blew my mind. (Participant 2, lines 126–135)
In addition to providing access to knowledge, low-threshold access points also generated knowledge by showing an interest in the illness and symptom experiences of their clients or members, actively collecting feedback on the effectiveness of available products, and summarizing this experiential knowledge to provide guidance and support for other clients.
(…) they’re keenly interested in what you’re specifically, you know your pain problems are and what your issues are and they, you know they’re interested in your feedback, like what has worked for you so that they can share information with other people. They’re careful not to give medical advice obviously, but they do want to hear back about whether what they’re doing is working, is helping people. (Participant 1, lines 179–184)
Being able to access this community-driven knowledge was an important part of becoming a medical cannabis user because all of our participants agreed that medicating with a plant involves some level “experimentation” (i.e., trying, reporting, adjusting, etc.) and “discovery” (i.e., achieving therapeutic relief with the right products, dosage, scheduling, etc.). Participants placed a lot of value on community-driven knowledge because it was generated from the experiences of peers (i.e., people with similar illnesses and symptoms) and addressed existing gaps in knowledge across the health care system. Participants were unanimous that, based on their experiences, health care providers were not knowledgeable about cannabis and had not played a role in their process of becoming (educated) medical cannabis users. They credited low-threshold access points for filling this knowledge gap.
But anybody, like, physicians, nurses or others I’ve discussed with are generally supportive of it, but they really don’t know much about it. And uh, like I know more about it, educating myself from hanging out at [name of access point], than medical professionals do, really. That’s what I perceive. Any medical professional I’ve talked about it to, I try to approach a few about it and, they’re generally supportive but they just don’t know anything about it (laughs). About cannabis and its benefits. (Participant 5, lines 252–261)
They also explained that legalization had resulted in the dismantlement of low-threshold access points (with the exception of VCBC and TMCD) and, as such, decreased access to knowledge. A number of participants explained that the only storefront access left in the community were licensed retail cannabis stores, which are not only prohibited from providing education and support to medical cannabis users but are also staffed with people who are new to cannabis and hired into retail jobs.
(…) generally I’d say no [medical cannabis users can’t access the information they need] because when I go to most of these retail stores, it just seems like it’s like, you know, some young twenty year old working a minimum wage job (laughs). You know, like if I’m like, hey um, “I want something to help me sleep” they’re just like, “oh here’s an Indica”, you know? (laughs). I’m like “well no-no-no, like I KNOW that, but like can you be more specific?” “No I can’t, I started this job two months ago, you know?” (laughs). (Participant 4, lines 276–281)
Accessing Medicine
Throughout the interviews, it was evident that achieving therapeutic relief with cannabis in a way that is effective, reliable, and consistent was a defining feature of becoming a medical cannabis user. However, this was only made possible by accessing the “right medicine” (i.e., the right product(s), at the right dosage, consumed at the right time, using the right mode of consumption) in a sustained manner, which was an important reason why participants relied on low-threshold access points as opposed to buying off the underground illegal market or at licensed retail stores after cannabis was legalized. Several participants explained the difference between accessing any kind of cannabis and accessing cannabis as a medicine (i.e., a substance that can provide therapeutic relief). They agreed that, in order to medicate with cannabis, you have to know what cannabis to look for, what you are using, and how. As one participant describes:
[buying off the street] was hit-and-miss, you didn’t always know that people were, would be there. And, lots of times it was really good pot and just, TOO strong sometimes. You know and, at [name of access point] you get to choose and ask questions about the pot, you know? And the other, buying off the street you just, get what you’re given. It was a reasonable deal, most of the time I got really good pot for ten bucks a gram so, no complaints (laughs). But it was just, you got the, you didn’t know what you were, what strain you were getting, whether it would be an Indica or a Sativa or how strong it would be. You know, you didn’t really know what to expect until you consumed it. (Participant 5, lines 169–177).
Being able to access cannabis in a reliable and consistent manner was also part of becoming a medical cannabis user. However, as noted by participants, the introduction of a mail-order medical cannabis program in the early 2000s and the opening of licensed retail stores following legalization in 2018 did not improve their access. Major barriers persisted because medical cannabis users need storefront access to a consistent supply of high quality cannabis products selected, developed, and packaged for medical use, and priced compassionately for medical cannabis users on a limited/fixed income who do not have any medical coverage. Before they were closed, with the exception of VCBC and TMCD as indicated above, low-threshold access points in British Columbia helped overcome these barriers.
(…) there was a couple of other [access points] that are shut down now that sort of made the point of providing good quality edibles and other products like salves, suppositories, things like that but at affordable prices so that people were, you know, so like a lot of high-dose stuff, like unless people are cutting it up in smaller bits, it’s not stuff that people are going to use recreationally. (Participant 3, lines 101–107)
According to all participants, what characterized low-threshold access points was the quality, diversity, and consistency of their cannabis products, the available dosages, and the desire to innovate by developing new products and provide access to existing products that are intended for medical use (i.e., products that have “no recreational value,” as noted by several participants including Participant 3). Low-threshold access points had made it possible for participants to access not any kind of cannabis, but the kind that they could medicate with. One participant who medicated with Rick Simpson oil (RSO) three times a day for chronic pain summarized it as such:
I am a firm believer, after many years of using [cannabis] myself and also listening to others, that the most effective way to get pain relief, physical pain relief is to use edible forms of cannabis and topical forms of cannabis. And so I do, three times a day. I use something that is called, the nickname is RSO, stands for Rick Simpson, is the man who invented a highly concentrated, very clean form of cannabis, edible cannabis. And (…) I purchase it at [name of access point] (…). It is such a game-saver (…) And this is all coming out of my pocket, on my very limited income so it’s very important to me to get, to be the most effective with my dosing. So RSO is the way to go for that. (Participant 10, lines 58–77, emphasis added)
The idea of “being effective with dosing,” as noted in the above quote, reiterates why participants accessed their medicine at low-threshold access points. In addition to having access to a community and a supply of high-quality cannabis products intended (and priced) for medical use, they were able to find the medicine that worked best for them and generated the most relief in the most inexpensive form possible. As such, cost-effectiveness was a major consideration when accessing medicine and an important reason why participants credited low-threshold access points for being able to medicate with cannabis. It was clear that becoming a medical cannabis user was conditional upon being able to afford the medicine in the first place. Participants were unanimous that affordability from the perspective of medical cannabis users is part of access and that having products available in licensed retail stores post-legalization, for example, did not provide them with more access nor the ability to “being effective with dosing.” As one participant explained:
I would say, it was nice how before cannabis got legalized and enforcement started taking place around some of these grey market access points, you could actually access edibles with a dosage high enough to be of use to someone like me, medically. I can’t afford to, nor do I want to buy, five packages of edibles every time I want to eat a fifty milligram dose because they’re not allowed to sell more than ten milligrams in a package legally. (Participant 11, lines 185–193)
Accessing Space
Accessing space, and more specifically a storefront space, was described as a core component of becoming a medical cannabis user since it requires learning from and talking to staff and peers, exploring various medical cannabis products (e.g., looking, touching, smelling, tasting, sampling), having a place to go for support and advice, and being able to visit based on ability to purchase or store products (e.g., number of visits and amounts purchased based on limited income and housing status). As such, storefront access played an important role in lowering the threshold to medical cannabis, as one participant explained:
(…) I walk through that door and I’m served immediately. Not forms and mail orders and waiting for it to arrive, you know, it’s there, immediately when I need it. Not some federal program that requires fields of interest being properly filled out and the bureaucratic nightmare of waiting and jumping through their hoops and on their agenda, on their time schedule. Daylight and darkness. (Participant 2, lines 336–340)
Storefront access is what made low-thresholds access points so important to medical cannabis users. These access points addressed a long-standing gap for people wanting to self-medicate with cannabis and people for whom the medical cannabis program did not offer the cannabis products they needed for therapeutic relief nor the steady supply of such products. Participants who had secured a medical authorization, in particular, noted how important storefront access had been for them and why the mail-order medical cannabis program fell short of meeting their needs as medical cannabis users. Prior to cannabis legalization storefront access had not been difficult for medical cannabis users.
Well there were even so-called medical marijuana places back before legalization too. They were all over the place, they even had them downtown, they had them on the [name of street]. [name of access point] was one of the places operating under the grey zone of medical marijuana before it went legal. So before it went legal there were a lot of places where you could get it. (Participants 9, lines 99–103)
In addition to reflecting on the importance of storefront access in the process of becoming a medical cannabis user, participants spoke of the importance of accessing a consumption space. Being able to sit with peers in a space where cannabis can be consumed safely created opportunities to learn from others and medicate more effectively.
(…) people were just sitting in there and everybody’s talking, so somebody else has rheumatoid arthritis, we start talking, like what works for you and what’s your, you know like, people get information from other clients too (…) sitting with somebody that has the same issue as you, it’s like, oh we’re in the same boat together. (Participant 6, lines 183–199)
For participants who were unhoused and precariously housed in multi-dwelling units (e.g., rooms, apartments, condos), in particular, being able to smoke/vape/vaporize in a dedicated and protected space was paramount. Numerous participants mentioned that smoking/vaping/vaporizing had become more difficult following legalization because of the introduction of new rules, the closure of low-threshold access points with consumption spaces, and the absence of legal consumption spaces. One participant described the shift from being able to smoke/vape/vaporize at home to being confronted by their landlord. While this participant was able to walk to another location, this was not reflective of all participants, especially those with limited mobility and those accessing public spaces where smoking/vaping/vaporizing is prohibited in British Columbia.
Well up until I started to get confronted by the landlord, I used to go out onto my balcony, it’s a third floor but in the last while, I walk down toward the beach (…). (Participant 8, lines 40–42)
Accessing a consumption space also helped participants identify as and identify with medical cannabis users, which in turn, helped break from the isolation they experienced as people living with chronic illnesses, symptoms, and disabilities. This compelling quote clearly illustrates this:
(…) I started going to [name of the consumption space] and I got to know all these people like I dunno, twenty or thirty different people, that I hadn’t known before and they were all kind of in similar circumstances as me. A lot of them had internal problems that weren’t um, you didn’t know what their problem was, you know? Or they had disabilities or mental disabilities, and I was thinking “oh wow, look at all these people, they’re trying to get by too, they’re on disability too, they’re you know, trying to buy pot and they got no money (laughs) and somebody helps them out”. And I experienced all that at [name of the consumption space], and it was wonderful because (…) when you’re on disability you kind of have to cobble a network of friends together for yourself, out of other disability people (laughs). But like that’s where [name of the consumption space] was indispensable in helping me do that and helping me, you know, develop my social skills. With a whole bunch of people, like the place was really busy there, many many times and you went in there it was just a cacophony of sound. You somehow fitted yourself in and have a conversation with somebody because somebody forced you to talk to them, you know? (laughs). It really, it was a community (…) It’s people’s living room. (Participant 5, lines 104–123)
Learning Across the Three Domains
Social learning was part of becoming a medical cannabis user. Even the most knowledgeable and experienced recreational cannabis users among our participants emphasized that learning to medicate with cannabis is a lot more complex than it may seem. They also noted that discovering therapeutic benefits while using cannabis for recreational purposes did not amount to knowing enough to medicate effectively or understanding the potential benefits of using cannabis for medical purposes.
So that’s what I got out of [name of access point], I met good friends and I just got educated about the actual medicinal benefits, ‘cause I didn’t know anything before that really. I knew there was medical benefits but it was, I had only used cannabis recreationally before 1997. (Participant 5, lines 157–160)
It is important to reiterate that learning in the context of becoming a medical cannabis user was never discussed on its own. It was always situated in the context of having low-threshold (sustained) access to community, medicine, and space. For example, one participant who was an experienced recreational cannabis smoker explained that gaining (sustained) access to edibles via a low-threshold access point is what created the conditions for them to learn how to manage pain and side effects with edibles and eventually how to substitute prescription opioids. This participant knew, from experience, that edibles “felt good” but needed the right combination of low-threshold access and learning to become a medical cannabis user.
(…) it was in 2007 because my teeth were in really bad shape and I was on really strong, under a doctor’s supervision, I was on really strong opiates and the side effects were really harsh and I was smoking cannabis to deal with it and the odd time I’d run into an edible from someone, like a cookie and I would feel good, like REALLY good for about a day or two (…) but they weren’t readily available in the black market (…) so that’s why I decided to go to the [name of access point] (…) because I really did see the value of the edibles at that point so that was about 2007, when I started taking edibles on a regular basis and using them initially just for side effects and then, you know, for substituting for opiates as well. (Participant 3, lines 31–45)
| Learning about medical cannabis | Learning how to medicate | Learning how to substitute |
|---|---|---|
|
•
Anatomy the plant
•
Types of plant and stains
•
Therapeutic components
•
Medical properties
•
Types of products
•
Dosages
•
Modes of consumption
•
Therapeutic benefits based on symptom and/or illness
•
Potential adverse effects
•
Quality assessment
•
Pricing
•
Medical access
|
•
Dosing effectively ◦
PRNa regimen
◦
Daily regimen
•
Combining products
•
Consuming products
•
Reducing potential harms (e.g., ingesting vs smoking)
•
Maximizing desired effects
•
Minimizing adverse or undesirable effects
•
Defining therapeutic relief and therapeutic goals
•
Monitoring symptoms/illness
•
Rationing and cost-saving
|
•
Substituting pharmaceuticals ◦
Partially
◦
Fully
•
Substituting one cannabis product for another
•
Substituting one mode of consumption for another
|
Discussion
Conclusion
Acknowledgments
Ethics Approval and Consent to Participate
Declaration of Conflicting Interests
Funding
ORCID iD
Footnote
1. Cannoil is a cannabis infused organic olive oil that can be ingested in oil or capsule format, used to make edibles, or applied to the skin as a topical massage oil, for example.

